Groundwork BioAg

Cover Block

PUBLIC

Attribute	Details
Name	Groundwork BioAg
Tagline	Develops and manufactures highly concentrated mycorrhizal inoculants for mainstream agriculture to boost yields and enable carbon projects.
Headquarters	Mazor, Israel
Founded	2014
Stage	Series B
Business Model	B2B
Industry	Agtech
Technology	Biotech / Life Sciences
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	$10M+
Total Disclosed	$29,000,000 [TheCompanyCheck]

Links

PUBLIC

• Website: https://groundworkbioag.com/
• LinkedIn: https://www.linkedin.com/company/groundwork-bioagriculture

Executive Summary

PUBLIC Groundwork BioAg develops highly concentrated mycorrhizal inoculants to address the dual pressures of agricultural productivity and soil carbon sequestration, a bet that has attracted nearly $30 million from a syndicate of climate-focused and strategic corporate investors [TheCompanyCheck] [CTech, August 2022]. Founded in 2014, the company was established to commercialize decades of proprietary research from Israel’s Volcani Center, which it exclusively licenses for its Rootella™ product line [Groundwork BioAg] [Middleland Capital]. The core proposition is a low-cost, scalable biological input that integrates into existing farming practices to improve nutrient uptake and crop yields while also generating quantifiable soil carbon for credit programs [Middleland Capital] [UBS].

Co-founders Yossi Kofman, David Zaidman, and Daniel Segal, all holding PhDs, built the company on this licensed scientific foundation, though detailed prior career histories are not prominent in public coverage. The business model is B2B, selling registered products to commercial growers and input distributors across North and South America, India, and Ukraine [Middleland Capital]. Following an $18 million Series B in 2022 led by Climate Innovation Capital, the company’s near-term trajectory hinges on scaling global commercialization and proving the revenue model for its carbon credit partnerships, such as the one announced with Anew Climate [CTech, August 2022] [Groundwork BioAg].

Data Accuracy: GREEN -- Core company facts and funding round corroborated by company press releases and multiple investor profiles.

Taxonomy Snapshot

Axis	Classification
Stage	Series B
Business Model	B2B
Industry / Vertical	Agtech
Technology Type	Biotech / Life Sciences
Geography	Global / Remote-First
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	$10M+ (total disclosed ~$29,000,000)

Company Overview

PUBLIC

Groundwork BioAg was established in 2014 in Mazor, Israel, with the explicit mission to commercialize mycorrhizal inoculants for large-scale, conventional farming [Groundwork BioAg]. The founding premise was to translate decades of academic research into a scalable biological input, a move anchored by a globally exclusive license agreement signed in January 2015 with Israel's Agricultural Research Organization (ARO), known as the Volcani Center [Groundwork BioAg, 2015]. This agreement covered both proprietary mycorrhizal strains and production methods, providing the company's initial technological foundation.

The company's development path followed a capital-intensive biotech model, securing an estimated $11 million in early strategic rounds before raising an $18 million Series B in August 2022 [TheCompanyCheck] [Groundwork BioAg, August 2022]. The Series B, led by Climate Innovation Capital, was earmarked for global commercialization and the development of carbon credit revenue streams for farmers [CTech]. Key operational milestones include the registration and sale of its Rootella™ product line in major agricultural regions including North America, South America, India, and Ukraine, and the establishment of a distributed team of approximately 51 employees across four continents as of late 2024 [Middleland Capital] [LeadIQ, 2024].

Data Accuracy: GREEN -- Confirmed by company press releases, investor profiles, and third-party employment data.

Product and Technology

MIXED

The company's commercial offering is a line of biological inoculants branded Rootella™, designed to be a low-friction input for large-scale agriculture. These products contain a high concentration of arbuscular mycorrhizal fungi, a type of beneficial soil microorganism that forms a symbiotic relationship with plant roots [Middleland Capital]. The core proposition is that applying Rootella during seeding or fertilizing routines improves nutrient and water uptake for the plant, leading to documented yield increases in major row crops like corn, soybean, and sorghum without requiring farmers to alter their existing cultivation practices [LinkedIn, Middleland Capital].

Groundwork BioAg's technical differentiation rests on two pillars: concentration and exclusive IP. The company describes its inoculants as "highly-concentrated" and "low-cost," a formulation advantage it attributes to proprietary production methods licensed exclusively from Israel's Agricultural Research Organization, the Volcani Center [Middleland Capital, Groundwork BioAg]. This foundational IP, secured via a global exclusive license agreement signed in January 2015, covers both the specific mycorrhizal strains and the manufacturing processes [Groundwork BioAg, 2015, Seed World]. The product line has expanded to include formulations for different applications, with Rootella L, Rootella X, and a powder form called Rootella Forte slated for display at industry events in 2025 [AgNewsWire, 2025].

The product strategy explicitly links agronomic benefits to climate outcomes, creating a dual value proposition. Beyond yield improvement, the company states that Rootella can "quantitatively support soil carbon sequestration and carbon credits" [Groundwork BioAg]. This positions the biological input as a tool for farmers to generate premium carbon revenue, a feature highlighted by climate-focused investors like Climate Innovation Capital [CTech, August 2022]. Commercially, [PUBLIC] registered Rootella products are sold for row crops in North America, South America, India, and Ukraine, and the company has also developed products for specialty crops including cannabis [Middleland Capital].

Data Accuracy: GREEN -- Product claims and IP details are consistently reported across the company website, investor materials, and third-party coverage.

Market Research

PUBLIC The market for agricultural biologicals, particularly mycorrhizal inoculants, is expanding beyond niche organic farming into mainstream commodity production, driven by a confluence of regulatory pressure, input cost volatility, and the nascent but powerful pull of carbon markets.

Quantifying the total addressable market for a specific product like Rootella requires navigating a mix of broad biologicals data and more targeted analogies. The global agricultural biologicals market was valued at approximately $12.9 billion in 2022 and is projected to reach $27.9 billion by 2030, growing at a compound annual rate of 10.1% [Fortune Business Insights, 2023]. Within this, the soil amendments segment, which includes microbial inoculants, represents a significant portion. A more direct, albeit analogous, market sizing comes from investor Middleland Capital, which positions Groundwork BioAg's target as the "$100+ billion global fertilizer market," suggesting the company's wedge is to displace a portion of synthetic inputs with a biological alternative [Middleland Capital]. This framing is critical, as it shifts the SAM from the smaller biologicals niche to the vast expenditure on conventional fertilizers.

Demand drivers are well-documented and multi-pronged. Regulatory momentum in the EU and North America aims to reduce synthetic fertilizer use to cut greenhouse gas emissions, creating a policy push for alternatives [European Commission, 2022]. Concurrently, fertilizer prices have exhibited extreme volatility following geopolitical disruptions, prompting growers to seek cost-stable, yield-preserving solutions [World Bank, 2022]. The most significant emerging tailwind is the agricultural carbon market. Programs that pay farmers for sequestering carbon in soil are scaling, creating a direct revenue stream that can subsidize the adoption of enabling technologies like mycorrhizal fungi. Groundwork explicitly targets this, stating Rootella can "quantitatively support soil carbon sequestration and carbon credits" [Groundwork BioAg].

Adjacent and substitute markets highlight both competition and opportunity. The broader biologicals sector includes biopesticides and biostimulants, which often share distribution channels and farmer education hurdles. Conventional fertilizer and precision agtech are primary substitutes; success depends on proving superior ROI through yield lift and input reduction. The voluntary carbon market itself is an adjacent sector, where credibility and measurement are paramount. Groundwork's collaboration with Anew Climate to commercialize soil carbon credits indicates it is not just selling an input but participating in the carbon value chain, a strategic expansion of its served market.

Global Agricultural Biologicals (2022) | 12.9 | $B
Projected Market (2030) | 27.9 | $B
Target Analogous Market (Fertilizer) | 100 | $B

The chart underscores the strategic choice: targeting the slower-growth but enormous fertilizer spend offers a larger theoretical ceiling than the fast-growing but smaller biologicals category alone. The growth projection for biologicals confirms the sector tailwinds, but the real market ambition, as framed by investors, is to capture share from the incumbent chemical input regime.

Regulatory and macro forces are largely favorable but carry execution risk. Supportive policies like the US Department of Agriculture's Partnerships for Climate-Smart Commodities fund practices that enhance soil carbon, directly aligning with Groundwork's value proposition [USDA, 2022]. However, the carbon credit ecosystem remains fragmented, with standards for measurement, reporting, and verification (MRV) still evolving. The company's ability to navigate these verification protocols and ensure farmer payouts will be as important as its microbial science for capturing the full value of the carbon tailwind.

Data Accuracy: YELLOW -- Market sizing figures are from third-party reports, but the $100B fertilizer target is an investor analogy, not a confirmed SAM. Tailwind citations are from public policy and commodity price sources.

Competitive Landscape

MIXED

Groundwork BioAg operates in a competitive field defined by established biological input giants and a growing cohort of startups, but its positioning is distinct: it focuses on high-concentration, low-cost mycorrhizal inoculants for mainstream row crops, a wedge between premium biologicals and commodity fertilizers.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Groundwork BioAg	High-concentration mycorrhizal inoculants (Rootella) for row crops; enables carbon credit revenue.	Series B ($29M total disclosed)	Exclusive Volcani Center tech for low-cost, concentrated production; focus on carbon project integration.	[Middleland Capital] [CTech, August 2022]

A competitive map for biological soil inputs can be segmented by product type and go-to-market. In the mycorrhizal inoculant segment, Groundwork faces competition from large agricultural input corporations like BASF and Bayer, which have their own microbial portfolios, and from specialized biologicals companies such as Pivot Bio (nitrogen-fixing microbes) and Indigo Ag (microbial and carbon market platform). Adjacent substitutes include traditional synthetic fertilizers, which are cheaper per unit but lack the soil health and carbon sequestration benefits, and other soil amendments like humic acids. The company's stated strategy of integrating into existing seeding and fertilizer routines without changing cultivation practices [Middleland Capital] is a direct counter to the adoption friction often associated with biologicals.

Groundwork's defensible edge today appears to be its exclusive, production-focused intellectual property from Israel's Volcani Center, which it claims enables a highly concentrated, low-cost product [Middleland Capital]. This cost advantage is critical for scaling in price-sensitive row crop agriculture. The edge is durable if the licensed production methods remain proprietary and difficult to replicate at scale, but it is perishable if a competitor develops a superior fermentation or formulation process. A second, emerging edge is its early-mover positioning in the ag-carbon credit space through partnerships like the one with Anew Climate [Private]. This creates a bundled value proposition (yield boost plus carbon revenue) that larger incumbents may be slower to orchestrate.

The company is most exposed in distribution and brand recognition. While it has registered products in multiple continents [Middleland Capital], its go-to-market relies on partnerships with distributors and larger input manufacturers, such as the agreement with ADAMA for the Chinese market [Private]. This creates dependency and limits direct farmer relationships. A competitor like Indigo Ag, with its established carbon program and direct grower network, could replicate the mycorrhizal-plus-carbon offering and use its existing trust and scale to outpace Groundwork. Furthermore, the company has not publicly demonstrated a broad portfolio beyond mycorrhizae, leaving it vulnerable to competitors with integrated suites of biologicals that address a wider range of plant stressors.

The most plausible 18-month competitive scenario hinges on the maturation of the voluntary soil carbon market. If carbon credit demand and methodologies solidify quickly, Groundwork's focused strategy and partnerships could make it an attractive acquisition target for a major input company seeking a validated carbon-enabling biological. In this case, Groundwork BioAg could be a winner. If, however, carbon credit adoption stalls or a larger player like Bayer successfully launches a competing mycorrhizal product through its vast channel, Groundwork could become a loser, squeezed on brand and distribution despite its technical advantages. Its fate is tied less to pure product efficacy and more to the speed at which the carbon revenue model gains mainstream agricultural acceptance.

Data Accuracy: YELLOW -- Competitive analysis is based on the company's stated positioning and limited named competitors; detailed funding and differentiator data for direct competitors VLS and Legume Technology is not publicly available in the cited research.

Opportunity

PUBLIC Groundwork BioAg’s core bet is that a low-cost, scalable biological input can become the default tool for farmers seeking to simultaneously boost yields, reduce fertilizer costs, and generate new revenue from soil carbon credits.

The headline opportunity is to become the category-defining biologicals platform for mainstream agriculture. The company’s exclusive license to Volcani Center technology underpins a product, Rootella™, that is engineered for high concentration and low cost, designed to integrate into existing farming practices without operational changes [Middleland Capital]. This positions it not as a niche organic product but as a mass-market input. The cited evidence for this reachable outcome includes registered products already selling in major agricultural regions across North and South America, India, and Ukraine, with demonstrated yield increases in staple crops like corn and soybean [LinkedIn, Middleland Capital]. The recent strategic collaboration with Anew Climate to commercialize 500,000 tons of soil carbon credits and an exclusive agreement with ADAMA for the Chinese market signal that major players are validating the dual yield-and-carbon value proposition, moving it from aspiration into commercial traction.

Growth scenarios for Groundwork BioAg hinge on which of its value propositions unlocks the fastest adoption.

Scenario	What happens	Catalyst	Why it's plausible
Carbon Credit Monetization	Rootella becomes the preferred biological for generating verified soil carbon credits, creating a recurring revenue stream from credit sales on top of product sales.	The Anew Climate partnership scales, proving the methodology and creating a predictable credit pipeline for farmers [Groundwork BioAg].	The carbon credit market for agriculture is nascent but growing; a simple, proven biological input that quantifiably supports sequestration is a key enabler. The partnership demonstrates commercial intent.
Input Distributor Standard	Major global fertilizer and input distributors (like ADAMA) embed Rootella as a standard offering, making it a default add-on at the point of seed or fertilizer purchase.	The exclusive commercial agreement with ADAMA expands beyond China to other global markets [Groundwork BioAg].	Distributors are seeking higher-margin, differentiated products. Rootella’s compatibility with existing application routines lowers the barrier to adoption for their vast sales networks.
Regulatory Tailwind	Governments or sustainability frameworks begin to mandate or heavily incentivize soil health practices, creating a step-function increase in demand for verified biological inputs.	A major agricultural policy (e.g., in the EU or US) incorporates soil carbon sequestration into subsidy programs or sustainability standards.	Regulatory pressure to reduce synthetic fertilizer use and sequester carbon is increasing globally. Groundwork’s products are already registered and commercial, positioning it to capture early policy-driven demand.

What compounding looks like is a classic two-sided flywheel. Early adoption by large-scale commercial farmers generates field performance data across diverse geographies and crop types. This dataset strengthens the company’s carbon quantification models, making credit generation more predictable and valuable, which in turn attracts more farmers seeking that revenue. Concurrently, proven efficacy and scale improve unit economics in manufacturing, allowing price reductions or margin expansion that further accelerates adoption. Evidence this is starting includes the global commercial footprint and the structured partnership with Anew, which implies a move from one-off sales to a systematic, data-driven credit generation platform.

The size of the win can be framed by looking at comparable ag-input companies and the total addressable market for biologicals. While a direct public peer is elusive, the broader biologicals segment is projected to reach a multi-billion dollar market in the coming years. A more concrete scenario-based valuation considers what Groundwork BioAg could be worth if it captures a single-digit percentage of the global row crop inoculant market, which spans tens of millions of hectares. If the carbon credit scenario plays out, the company’s value could compound beyond typical input company multiples by layering a high-margin, recurring software-like revenue stream (credit monetization) on top of a physical product. This scenario suggests an outcome where the company evolves from a product supplier into a vertically integrated soil health platform, a transition that has historically commanded significant valuation premiums in agtech (scenario, not a forecast).

Data Accuracy: YELLOW -- Core product claims and partnership announcements are well-sourced from the company and investors. Market sizing and detailed valuation comparables are not publicly available in cited sources.

Sources

PUBLIC

1. [Groundwork BioAg] Mycorrhizal Fungi, Carbon Sequestration & Removal Inoculants - Groundwork BioAg | https://groundworkbioag.com/

2. [Middleland Capital] Middleland Capital Portfolio - Groundwork BioAg | https://www.middlelandcapital.com/portfolio/groundwork-bioag/

3. [TheCompanyCheck] Groundwork BioAg - Company Summary | https://www.thecompanycheck.com/company/b/groundwork-bioag/cunl77mha8csr7hoh

4. [CTech, August 2022] Groundwork BioAg completes $18 million Series B round to decarbonize mainstream agriculture | https://www.calcalistech.com/ctechnews/article/rkd8ihor5

5. [Groundwork BioAg, August 2022] GROUNDWORK BIOAG RAISES $18 MILLION TO ACCELERATE DECARBONIZATION OF MAINSTREAM AGRICULTURE | https://groundworkbioag.com/groundwork-bioag-raises-18-million-to-accelerate-decarbonization/

6. [LinkedIn] Groundwork BioAg | LinkedIn | https://www.linkedin.com/company/groundwork-bioagriculture

7. [LeadIQ, 2024] Groundwork BioAg - Company Profile | https://www.leadiq.com/company/groundwork-bioag

8. [Groundwork BioAg, 2015] Groundwork BioAg Announces Exclusive License Agreement with Israel's Volcani Center | https://groundworkbioag.com/groundwork-bioag-announces-exclusive-license-agreement-with-israels-volcani-center/

9. [Seed World] Groundwork BioAg Secures Exclusive License for Volcani Center Technology | https://seedworld.com/groundwork-bioag-secures-exclusive-license-for-volcani-center-technology/

10. [AgNewsWire, 2025] Groundwork BioAg to Showcase Rootella Product Line at Commodity Classic 2025 | https://agnewswire.com/groundwork-bioag-commodity-classic-2025/

11. [UBS] Global Visionaries: Groundwork BioAg | https://www.ubs.com/global/en/sustainability-impact/social-impact-and-philanthropy/globalvisionaries/visions/gv-profile/groundwork.html

12. [Fortune Business Insights, 2023] Agricultural Biologicals Market Size, Share & Industry Analysis | https://www.fortunebusinessinsights.com/agricultural-biologicals-market-102570

13. [European Commission, 2022] EU Soil Strategy for 2030 | https://environment.ec.europa.eu/topics/soil-and-land/soil-strategy_en

14. [World Bank, 2022] Commodity Markets Outlook: The Impact of the War in Ukraine on Commodity Markets | https://www.worldbank.org/en/publication/commodity-markets

15. [USDA, 2022] Partnerships for Climate-Smart Commodities | https://www.usda.gov/climate-solutions/climate-smart-commodities